Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Savient: Recommending A Switch Into Discovery Laboraratories (SVNT, $2.31)

I have decided to go the sidelines on Savient (current price of $2.31) and I am recommending a switch into…
Read more…

John Johnson Resigns as CEO, After Thinking It Over, I Continue with My Buy Recommendation (SVNT, $2.27)

The decision of John Johnson to go to Dendreon as CEO and Chairman after only one year at the helm…
Read more…

How Big is the Chronic Refractory Gout Market Addressed by Krysrexxa? (SVNT, $2.28)

Introduction
The size of the chronic refractory gout market that Krystexxa targets have been a concern to investors and some believe…
Read more…

Initiating Coverage of Savient Pharmaceuticals with a Buy: Initial Launch of Krystexxa Has Been Disappointing but I Believe That This is a Breakrhrough Drug with Great Potential (SVNT, $2.35)

Investment Opinion
I am recommending purchase of Savient Pharmaceuticals at the current price of $2.35. My recommendation is based on the…
Read more…